Evidation Health Raises $30M in Series C Venture Capital Funding

Evidation Health, a San Mateo, Calif.-based health and measurement company, raised $30m in Series C funding.

The round was co-led by SV Health Investors, a new investor, and existing investor B Capital Group. It included participation from existing investors GE Ventures and Sanofi Ventures. With this funding, Evidation has raised a total of $61m. In conjunction with the funding, SV Health Investors Managing Partner Michael Balmuth, is joining Evidation’s board of directors.

Led by CEO Deborah Kilpatrick, Ph.D., Evidation Health enables life sciences and health care companies to understand how everyday behaviors and health interact. The company also announced that it launched a new data platform to enable its customers to analyze and process large-scale sensor and behavior data in clinically meaningful ways.
By linking real world data from smartphones and connected sensors — including wearables and medical devices — with traditional medical data, Evidation measures how behaviors outside of the doctor’s office or hospital relate to health and impact outcomes. The new data platform — which has been battle tested in a pilot program with a global pharmaceutical company — can ingest individually-permissioned data from more than 100 sources ranging from Apple Health to Fitbit, Epic, Blue Button, and Dexcom.
The platform combines this information with traditional data from insurance claims, electronic health records, and diagnostic reports, alongside patient-reported outcomes collected directly to provide a new way to analyze individual behavior and health in real time.
It currently processes more than 1 trillion data points each year across millions of individuals, being used to invent new ways to measure health across diabetes and cognitive decline. This complements the work that the company is performing with partners across multiple therapeutic areas ranging from cardiovascular disease to chronic pain, rheumatoid arthritis, migraine, depression and anxiety, fatigue, heart failure, and asthma — to name a few.

In addition to supporting the new data platform, the funding will be used to develop partnerships, adding to Evidation’s vast array of real world data sources, and to launch novel research studies to better understand and measure how everyday behavior and health interact.



Join the discussion